Back to Corporate News Overview
Put companies on watchlist
Xlife Sciences AG
ISIN: CH0461929603
WKN: A2PK6Z
About
Company Snapshot
GO
AI
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

AI
EN GIF 300X250
Xlife Sciences AG · ISIN: CH0461929603 · EQS - adhoc news (79 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1892329
EQS News
Directors Dealings
Analyst Ratings
Short Seller
Technical Analysis
Levermann Score
30 April 2024 07:00AM

Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report

Xlife Sciences AG / Key word(s): Market Report/Study results
Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report

30-Apr-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Zurich, 30st of April 2024: Xlife Sciences AG (SIX: XLS) released the 2023 Valuation Report today, which assesses the company's portfolio as of the end of 2023. The evaluation was conducted by the independent consulting firm CYLAD Experts and covers 18 of the total 25 project companies of Xlife Sciences1. The assessment is primarily based on the risk-adjusted net present value (rNPV), commonly used in the life sciences industry. The main parameters of the valuation process are the cost of capital and the development risks of the involved project companies.

The 2023 Valuation Report values Xlife Sciences' portfolio as of December 31, 2023, in a range between CHF 611.7 million (previous year: CHF 576 million) and CHF 747.8 million (previous year: CHF 704.5 million).

  • The six project companies alytas therapeutics GmbH, Veraxa Biotech AG, inflamed pharma GmbH, Inventum Genetics GmbH, FUSE-AI GmbH, and 4D Lifetec AG account for 84 percent of this portfolio value.
  • The «Biotechnology/Therapies» sector contributes 55 percent of the portfolio value, while the «Technology Platforms» sector accounts for 28 percent.
  • 70 percent of the evaluated portfolio is in the «Proof of Concept» phase, with an additional 20 percent in the clinical development phase.

Oliver R. Baumann, CEO of Xlife Sciences, states: «The 2023 Valuation Report confirms and underscores the long term portfolio potential of Xlife Sciences. It demonstrates that our focus on projects in an early to very early stage depending on the future success of the individual project companies - can create significant leverage for our shareholders.»

The complete 2023 Valuation Report from Xlife Sciences is available for download at https://www.xlifesciences.ch/en/news-and-key-figures in the «Financial Reports» section.

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch, 
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange


News Source: Xlife Sciences AG

End of Inside Information
Language: English
Company: Xlife Sciences AG
Talacker 35
8001 Zürich
Switzerland
Phone: +41 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
Valor: A2PK6Z
Listed: SIX Swiss Exchange
EQS News ID: 1892329

 
End of Announcement EQS News Service

1892329  30-Apr-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1892329&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Xlife Sciences AG

SIX:XLS Price indication powered by TradingView

Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.

The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.

1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.